Myocardial Infarction News and Research

RSS

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Milliman Care Guidelines presents Doyle Award to ADVANTAGE Health Solutions and Sound Physicians

Milliman Care Guidelines today presented its Doyle Award for Innovation and Leadership in Healthcare to ADVANTAGE Health Solutions, Inc.(SM) and to Sound Physicians. The awards were presented in ceremonies here at the Milliman Care Guidelines Client Forum.

5 Apr 2011

La Jolla acquires GliaMed's novel class of compounds

La Jolla Pharmaceutical Company today announced that it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands from privately held GliaMed, Inc.

5 Apr 2011

Both radial and femoral approaches are safe and effective for angioplasty

In the future you may hear the doctor say: "Give me your arm and I'll do some heart surgery."

5 Apr 2011

Implementation of STEMI guidelines, protocols in hospitals without cardiac catheterization labs improves dramatically

The implementation of acute heart attack or ST-elevation myocardial infarction (STEMI) guidelines, protocols and standing orders in Minnesota community hospitals without cardiac catheterization labs has dramatically improved since 2003, according to a scientific poster that will be presented at the American College of Cardiology (ACC) Scientific Sessions in New Orleans, April 1-3.

5 Apr 2011

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies, announced today the results of a healthy volunteers Phase I clinical study of Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury.

4 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Boston Scientific Corporation today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION Platinum Chromium Paclitaxel-Eluting Stent System compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

4 Apr 2011

Regado's REG1 system Phase 2b trial results presented at i2 Summit

Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.

4 Apr 2011

NeoStem revenues increase 13% for the year ended December 31, 2010

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, is today providing unaudited results for 2010 and an update of recent activities.

2 Apr 2011

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

A novel cardiac biomarker, ST2, will be highlighted in three presentations at the American College of Cardiology in New Orleans this week.

1 Apr 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

POET-COPD study looks at controlling 'lung attacks' which can lead to increased ER visits

Chronic Obstructive Pulmonary Disease (COPD) is a major cause for hospital stays and emergency room visits across Canada and researchers say minimizing exacerbations or flare-ups of the disease can go a long way to reducing hospitalizations.

25 Mar 2011

$Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty$

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Medtronic of Canada Ltd. today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients.

23 Mar 2011

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

In patients with a suspected acute coronary syndrome (ACS; such as heart attack or unstable angina), use of a more sensitive test to detect the protein troponin in blood was associated with increased diagnosis of a heart attack and improved identification of patients at high risk of another heart attack and death in the following year, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold

RegeneRx Biopharmaceuticals, Inc. announced that it has received a notice from the U.S. Food and Drug Administration (FDA) indicating that, due to non-compliance with FDA's current Good Manufacturing Practice (cGMP) regulations by its contract manufacturer, the Company's Phase 2 clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold.

16 Mar 2011

New study examines mortality rates among patients treated for AMI in hospitals

A new Yale University study looks at why there is such a big difference in the mortality rates among patients treated for heart attacks in hospitals across the country. The study appears in the March issue of the Annals of Internal Medicine.

16 Mar 2011

Myocardial Infarction News and Research

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Milliman Care Guidelines presents Doyle Award to ADVANTAGE Health Solutions and Sound Physicians

La Jolla acquires GliaMed's novel class of compounds

Both radial and femoral approaches are safe and effective for angioplasty

Implementation of STEMI guidelines, protocols in hospitals without cardiac catheterization labs improves dramatically

Stealth announces Bendavia Phase I clinical study results against ischemia reperfusion injury

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Regado's REG1 system Phase 2b trial results presented at i2 Summit

NeoStem revenues increase 13% for the year ended December 31, 2010

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Genentech's Lucentis Phase III trials in DME meets primary endpoints

POET-COPD study looks at controlling 'lung attacks' which can lead to increased ER visits

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

More sensitive test to detect protein troponin associated with increased diagnosis of heart attacks

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold

New study examines mortality rates among patients treated for AMI in hospitals

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News